Predictors and outcomes of venous thromboembolism in hospitalized lung cancer patients: A Nationwide Inpatient Sample database analysis. Issue 1 (April 2015)

• Record Type: Journal Article
• Authors: Steuer, Conor E.; Behera, Madhusmita; Kim, Sungjin; Patel, Nikita; Chen, Zhengjia; Pillai, Rathi; Saba, Nabil F.; Shin, Dong M.; Owonikoko, Taofeek K.; Khuri, Fadlo R.; Ramalingam, Suresh S.
• Is Part Of: Lung cancer. Volume 88:Issue 1(2015:Apr.)
• Page Start: 80
• Page End: 84
• Publication Date: 2015-04
• Subjects: Thromboembolism -- Lung cancer -- VTE -- Outcomes -- Utilization; Lungs -- Cancer -- Periodicals; Lung Neoplasms -- Abstracts; Lung Neoplasms -- Periodicals; Poumons -- Cancer -- Périodiques; Lungs -- Cancer; Periodicals; Electronic journals; Electronic journals; 616.99424
• DOI: 10.1016/j.lungcan.2015.01.022
• Languages: English
• ISSNs: 0169-5002

Abstract

Highlights: We identify hospitalized lung cancer patients with VTE and those without. We examine the clinical predictors and outcomes of VTE in this population. Certain demographic groups are at higher risk of VTE. VTE diagnosis negatively impacts clinical outcome. There is a significant increased healthcare costs in patients with VTE. Abstract: Background: Patients with lung cancer are at high risk of developing venous thromboembolism (VTE), including deep venous thrombosis and pulmonary embolism. We sought to characterize the clinical factors associated with development of VTE and the impact of VTE on outcomes for hospitalized lung cancer patients. Methods: We analyzed data captured in the Nationwide Inpatient Sample (NIS) database of the Agency of Healthcare Research and Quality (AHRQ). The study included all lung cancer patients hospitalized between 2006 and 2010 who had VTE captured as one of the top three discharge diagnoses. Demographics and outcomes of this population were compared to those of inpatient lung cancer patients without a VTE diagnosis. All analyses were performed using SAS version 9.3. Results: Out of 570, 304 lung cancer hospitalizations, 20, 672 had a clinically relevant diagnosis of VTE, accounting for 3.6% of all events. The median age of lung cancer patients with VTE was 68 years; 48% were females, 79% were Caucasians, and 43% had metastatic disease. When compared to a lung cancer cohort without VTE ( n = 502, 153), patients with VTE had significantly longer length of stay (LOS) (7.15 days vs. 6.05 days, OR 1.12), higher inpatient mortality (10.03% vs. 8.69%, OR 1.06), higher total hospital charges ($43, 800 vs. $37, 800, OR 1.07), and greater likelihood of moderate to severe disability upon discharge (55% vs. 49%, OR 1.23). Conclusions: VTE in hospitalized lung cancer patients is associated with longer LOS, higher inpatient mortality rates, increased cost and greater disability upon discharge compared to other inpatient lung cancer patients.